Download MendeleyDiscovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay.
Chen, Z., Zhang, H., Liu, S., Xie, Y., Jiang, H., Lu, W., Xu, H., Yue, L., Zhang, Y., Ding, H., Zheng, M., Yu, K., Chen, K., Jiang, H., Luo, C.(2017) Medchemcomm 8: 1322-1331
- PubMed: 30108844 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1039/c7md00083a
- Primary Citation Related Structures:
5H21 - PubMed Abstract:
As a member of the bromodomain and extra terminal domain (BET) protein family, BRD4 is closely related to cancers and other diseases. Small-molecule BRD4 inhibitors have already demonstrated promising potential for the therapy of BRD4-related cancers. In this study, we report the discovery and evaluation of a novel category of BRD4 inhibitors, which share a trimethoxy ring and target the first bromodomain of the human BRD4 protein. The IC 50 value of the most potent compound, DC-BD-03, is 2.01 μM. In addition, a high-resolution crystal structure of the compound DC-BD-29 with the first bromodomain of BRD4 was determined, which revealed the binding mode and facilitated further structure-based optimization. These compounds exhibited anti-proliferation activity, caused cell cycle arrest, and induced apoptosis in human leukemia MV4-11 cells. Thus, the results presented in this study indicated the potential of this series of compounds as drug candidates for the therapy of BRD4-related cancers.
- Drug Discovery and Design Center , State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica , Chinese Academy of Sciences , 555 Zuchongzhi Road , Shanghai 201203 , China . Email: 10110700070@fudan.edu.cn ; Email: hding@simm.ac.cn ; Email: cluo@simm.ac.cn ; Tel: +86 21 50806600.
Organizational Affiliation:
